Literature DB >> 21191017

Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines.

Silvia Loureiro1, Junyuan Ren, Pongsathon Phapugrangkul, Camilo A Colaco, Christopher R Bailey, Holly Shelton, Eleonora Molesti, Nigel J Temperton, Wendy S Barclay, Ian M Jones.   

Abstract

The hemagglutinins (HAs) of human H1 and H3 influenza viruses and avian H5 influenza virus were produced as recombinant fusion proteins with the human immunoglobulin Fc domain. Recombinant HA-human immunoglobulin Fc domain (HA-HuFc) proteins were secreted from baculovirus-infected insect cells as glycosylated oligomer HAs of the anticipated molecular mass, agglutinated red blood cells, were purified on protein A, and were used to immunize mice in the absence of adjuvant. Immunogenicity was demonstrated for all subtypes, with the serum samples demonstrating subtype-specific hemagglutination inhibition, epitope specificity similar to that seen with virus infection, and neutralization. HuFc-tagged HAs are potential candidates for gene-to-vaccine approaches to influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21191017      PMCID: PMC3067967          DOI: 10.1128/JVI.01241-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies.

Authors:  Nikolai V Kaverin; Irina A Rudneva; Elena A Govorkova; Tatyana A Timofeeva; Aleksandr A Shilov; Konstantin S Kochergin-Nikitsky; Piotr S Krylov; Robert G Webster
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

Review 2.  Recombinant vaccines for influenza virus.

Authors:  Ralph A Tripp; S Mark Tompkins
Journal:  Curr Opin Investig Drugs       Date:  2008-08

3.  Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.

Authors:  Mei-Yun Zhang; Yanping Wang; Marie K Mankowski; Roger G Ptak; Dimiter S Dimitrov
Journal:  Vaccine       Date:  2008-12-10       Impact factor: 3.641

4.  Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies.

Authors:  Arun K Kashyap; John Steel; Ahmet F Oner; Michael A Dillon; Ryann E Swale; Katherine M Wall; Kimberly J Perry; Aleksandr Faynboym; Mahmut Ilhan; Michael Horowitz; Lawrence Horowitz; Peter Palese; Ramesh R Bhatt; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-14       Impact factor: 11.205

5.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

Review 6.  Progress on baculovirus-derived influenza vaccines.

Authors:  Manon M J Cox
Journal:  Curr Opin Mol Ther       Date:  2008-02

7.  An avian influenza H5N1 virus that binds to a human-type receptor.

Authors:  Prasert Auewarakul; Ornpreya Suptawiwat; Alita Kongchanagul; Chak Sangma; Yasuo Suzuki; Kumnuan Ungchusak; Suda Louisirirotchanakul; Hatairat Lerdsamran; Phisanu Pooruk; Arunee Thitithanyanont; Chakrarat Pittayawonganon; Chao-Tan Guo; Hiroaki Hiramatsu; Wipawee Jampangern; Supamit Chunsutthiwat; Pilaipan Puthavathana
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

8.  Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity.

Authors:  Zhi-Yong Yang; Chih-Jen Wei; Wing-Pui Kong; Lan Wu; Ling Xu; David F Smith; Gary J Nabel
Journal:  Science       Date:  2007-08-10       Impact factor: 47.728

9.  Interaction of severe acute respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting enzyme-2.

Authors:  Alison C Mathewson; Alexandra Bishop; Yongxiu Yao; Fred Kemp; Junyuan Ren; Hongying Chen; Xiaodong Xu; Ben Berkhout; Lia van der Hoek; Ian M Jones
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

10.  Immunogenicity of the outer domain of a HIV-1 clade C gp120.

Authors:  Hongying Chen; Xiaodong Xu; Ian M Jones
Journal:  Retrovirology       Date:  2007-05-17       Impact factor: 4.602

View more
  13 in total

1.  A novel synthetic bipartite carrier protein for developing glycotope-based vaccines.

Authors:  Hsiao-Ling Chiang; Chi-Yu Lin; Fan-Dan Jan; Yaoh-Shiang Lin; Chia-Tse Hsu; Jacqueline Whang-Peng; Leroy F Liu; Shin Nieh; Chun-Cheng Lin; Jaulang Hwang
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

2.  Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.

Authors:  Fei Yu; Ye Li; Yan Guo; Lili Wang; Jie Yang; Guangyu Zhao; Yusen Zhou; Lanying Du; Shibo Jiang
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.

Authors:  Xiaoling Tang; Joo R Lee; Asiya Chida; Asheley P Chapman; Kristina Mercer; Rebekah E Wharton; Markus Kainulainen; Jennifer L Harcourt; Roosecelis B Martines; Michelle Schroeder; Liangjun Zhao; Anton Bryksin; Bin Zhou; Eric Bergeron; Brigid C Bollweg; Azaibi Tamin; Natalie Thornburg; David E Wentworth; David Petway; Dennis A Bagarozzi; M G Finn; Jason M Goldstein
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

Review 4.  Pseudotype-based neutralization assays for influenza: a systematic analysis.

Authors:  George William Carnell; Francesca Ferrara; Keith Grehan; Craig Peter Thompson; Nigel James Temperton
Journal:  Front Immunol       Date:  2015-04-29       Impact factor: 7.561

5.  CFP10: mFcγ2 as a novel tuberculosis vaccine candidate increases immune response in mouse.

Authors:  Ali Asghar Baghani; Saman Soleimanpour; Hadi Farsiani; Arman Mosavat; Masoud Yousefi; Zahra Meshkat; Seyed Abdolrahim Rezaee; Saeid Amel Jamehdar; Mohammad Reza Akbari Eydgahi; Hamid Sadeghian; Kiarash Ghazvini
Journal:  Iran J Basic Med Sci       Date:  2017-02       Impact factor: 2.699

6.  Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen.

Authors:  Mun Peak Nyon; Lanying Du; Chien-Te Kent Tseng; Christopher A Seid; Jeroen Pollet; Kevin S Naceanceno; Anurodh Agrawal; Abdullah Algaissi; Bi-Hung Peng; Wanbo Tai; Shibo Jiang; Maria Elena Bottazzi; Ulrich Strych; Peter J Hotez
Journal:  Vaccine       Date:  2018-02-26       Impact factor: 3.641

7.  A Highly Expressing, Soluble, and Stable Plant-Made IgG Fusion Vaccine Strategy Enhances Antigen Immunogenicity in Mice Without Adjuvant.

Authors:  Andrew G Diamos; Mary D Pardhe; Haiyan Sun; Joseph G L Hunter; Jacquelyn Kilbourne; Qiang Chen; Hugh S Mason
Journal:  Front Immunol       Date:  2020-12-04       Impact factor: 7.561

8.  Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity.

Authors:  Claudine Porta; Xiaodong Xu; Silvia Loureiro; Saravanan Paramasivam; Junyuan Ren; Tara Al-Khalil; Alison Burman; Terry Jackson; Graham J Belsham; Stephen Curry; George P Lomonossoff; Satya Parida; David Paton; Yanmin Li; Ginette Wilsden; Nigel Ferris; Ray Owens; Abhay Kotecha; Elizabeth Fry; David I Stuart; Bryan Charleston; Ian M Jones
Journal:  J Virol Methods       Date:  2012-11-19       Impact factor: 2.014

9.  A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.

Authors:  Lanying Du; Guangyu Zhao; Shihui Sun; Xiujuan Zhang; Xiaojun Zhou; Yan Guo; Ye Li; Yusen Zhou; Shibo Jiang
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

Review 10.  Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.

Authors:  Kyle Saylor; Frank Gillam; Taylor Lohneis; Chenming Zhang
Journal:  Front Immunol       Date:  2020-02-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.